Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...
The company’s pipeline products include ABX-002, a CNS-directed thyroid hormone receptor beta (TRß) agonist against treats Adjunctive major depressive disorder (MDD), bipolar depression and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback